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According to the World Health Organization, about 2 billion
persons worldwide have been infected with hepatitis B virus
(HBV). More than 350 million are chronically infected
worldwide with a high risk of developing liver cirrhosis
andhepatocellularcarcinoma(HCC)(representing1million
deaths per year). The epidemiology of HCC is peculiar
with both geographic and temporal patterns of incidence
paralleling exposure to viral etiologic factors. The highest
HCC incidence rates are areas endemic for chronic infection
with hepatitis B virus (Asia and Africa). Based on sequence
divergence in the entire genome of >8%, HBV genomes
have been classiﬁed into eight groups designated from A
to H. The genotypes of HBV have distinct geographical
distributions. Although preliminary clinical studies seem to
indicate that there is an association between HBV genotype
and natural history of infection and/or response to antiviral
therapy, further evaluations on larger collectives of patients
are necessary to give a clearer picture of the subject. The ﬁrst
paper of this special issue addresses the aetiology and picture
of CTNNB1 and TP53 mutations in Thailand patients with
HCC and provides a detailed study of the situation in an
Asian country. The second paper presents the study on the
etiology and viral genotypes in Colombia; these data are not
common with South America. The two subsequent papers
address the question of HBV variability and HCC in two
diﬀerent countries and continents. Indeed, the third paper is
on TP53 mutations and HBx gene of hepatitis B virus status
inHCCinIran.Itisbringinginterestingdiscussionaboutthe
potential link between HBV genotypes and TP53 mutation
R249S. The fourth paper of this special issue presents a fully
picture of viral hepatitis viruses and TP53 mutations in HCC
from Columbia. The ﬁfth paper describes the evolution of
HBV “quasispecies” in a chronic HBV chronic carrier over a
2-year period. The ﬁnal paper of this special issue proposes
an original study on the importance of HBV variability on
RNAi strategies.
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